RxDoctor Payments Data

Inderpreet Sachar, MD

Geriatric Medicine · Hackensack, NJNPI 1619141561

Payments from drug & device makers

$673in general payments, 2019–2025

Across 21 payments — averaging $32.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$146
  • AbbVie$125
  • Novo Nordisk$122
  • Johnson & Johnson$59
  • UCB, Inc.$37
  • Otsuka America Pharmaceutical, Inc.$36
  • plus $148 from 7 others

What the payments were for

  • Food & beverage$673100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$673 in reported general payments places this provider in the 55th percentile of 165 geriatric medicine providers in New Jersey.

See all geriatric medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$253,634
Medicare patients
402
Services billed
2,584

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban257$164,092
JanuviaSitagliptin Phosphate56$34,355
JardianceEmpagliflozin47$32,185
MyrbetriqMirabegron57$26,484
XareltoRivaroxaban33$20,759
EntrestoSacubitril/Valsartan22$14,120
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$13,085
OzempicSemaglutide13$12,899
FarxigaDapagliflozin Propanediol21$12,567
TradjentaLinagliptin15$8,081
Divalproex Sodium214$8,036
Breo ElliptaFluticasone/Vilanterol14$7,857
LinzessLinaclotide11$6,145
Midodrine Hcl68$5,624
GemtesaVibegron11$5,562

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$12$40,26662 claims
Astellas Pharma US IncMyrbetriq$25$26,48457 claims
GSKTrelegy Ellipta, Breo Ellipta$16$20,94237 claims
Johnson & JohnsonXarelto$59$20,75933 claims
Novo NordiskOzempic$122$12,89913 claims
AbbVieLinzess$125$6,14511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 165 geriatric medicine providers in New Jersey.

Other geriatric medicine in Hackensack

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →